Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors

Executive Summary

In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.

Advertisement

Related Content

Increasing Optionality For Licensors, Rise Of Small-Cap Partners Ongoing
Gene Therapy Reimbursement: Is Blindness A Bad First Test?
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
CEPI Global Vaccines Launch May Augur Creation Of Credible Davos Deal
Head of Bayer LifeScience Center: Expect More JVs
Algeta and Bayer agree $2.9bn sweetened takeover

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel